Local excision after preoperative chemoradiotherapy for rectal cancer: Results of a multicenter phase II clinical trial

Diseases of the Colon and Rectum

Volumn 56, Issue 12, 2013, Pages 1349-1356

  Pucciarelli, Salvatore ^a   De Paoli, Antonino ^b   Guerrieri, Mario ^c   La Torre, Giuseppe ^d   Maretto, Isacco ^a   De Marchi, Francesco ^b   Mantello, Giovanna ^e   Gambacorta, Maria Antonietta ^f   Canzonieri, Vincenzo ^b   Nitti, Donato ^a   Valentini, Vincenzo ^f   Coco, Claudio ^f  

^a UNIVERSITY OF PADOVA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e State Hospital   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chemoradiotherapy; Local control; Local excision; Rectal cancer

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84888354365     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e3182a2303e     Document Type: Article

References (41)

1. National Comprehensive Cancer Network, Inc. NCCN guidelines version 4.2013: rectal cancer. http://www.nccn.org/professionals/ physician-gls/pdf/ rectal.pdf. Updated. Accessed March 26, 2013.
2. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30: 1926-1933.
3. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24: 4620-4625.
4. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11: 835-844.
5. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99: 918-928.
6. Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29: 3163-3172.
7. Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30: 1770-1776.
8. Sauer R, Becker H, Hohenberger W, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351: 1731-1740.
9. Pucciarelli S, Del Bianco P, Efficace F, et al. Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg. 2011;253: 71-77.
10. Pucciarelli S, Gagliardi G, Maretto I, et al. Long-term oncologic results and complications after preoperative chemoradiotherapy for rectal cancer: a single-institution experience after a median follow-up of 95 months. Ann Surg Oncol. 2009;16: 893-899.
11. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240: 711-717.
12. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29: 4633-4640.
13. Dalton RS, Velineni R, Osborne ME, et al. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Colorectal Dis. 2012;14: 567-571.
14. Mohiuddin M, Marks G, Bannon J. High-dose preoperative radiation and full thickness local excision: a new option for selected T3 distal rectal cancers. Int J Radiat Oncol Biol Phys. 1994;30: 845-849.
15. Schell SR, Zlotecki RA, Mendenhall WM, Marsh RW, Vauthey JN, Copeland EM 3rd. Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy. J Am Coll Surg. 2002;194: 584-590.
16. Kim CJ, Yeatman TJ, Coppola D, et al. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234: 352-358.
17. Lezoche E, Guerrieri M, Paganini AM, Feliciotti F. Long-term results of patients with pT2 rectal cancer treated with radiotherapy and transanal endoscopic microsurgical excision. World J Surg. 2002;26: 1170-1174.
18. Callender GG, Das P, Rodriguez-Bigas MA, et al. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol. 2010;17: 441-447.
19. Ruo L, Guillem JG, Minsky BD, Quan SH, Paty PB, Cohen AM. Preoperative radiation with or without chemotherapy and fullthickness transanal excision for selected T2 and T3 distal rectal cancers. Int J Colorectal Dis. 2002;17: 54-58.
20. Ahmad NR, Nagle DA. Sphincter preservation in rectal cancer. Preoperative radiation therapy followed by local excision. Semin Radiat Oncol. 1998;8: 36-38.
21. Borschitz T, Wachtlin D, Möhler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol. 2008;15: 712-720.
22. Nair RM, Siegel EM, Chen DT, et al. Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. J Gastrointest Surg. 2008;12: 1797-1805.
23. Lezoche G, Baldarelli M, Guerrieri M, et al. A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc. 2008;22: 352-358.
24. Bujko K, Richter P, Smith FM, et al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical reoperation for poor responders: a prospective multicentre study. Radiother Oncol. 2013;106: 198-205.
25. Coco C, Rizzo G, Mattana C, et al. Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. Surg Endosc. 2013;27: 2860-2867.
26. Pomerri F, Pucciarelli S, Maretto I, et al. Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. Surgery. 2011;149: 56-64.
27. Greene FL, Page DL, Fleming ID, et al. (eds) AJCC cancer staging manual. Sixth Edition. New York: Springer-Verlag, 2002.
28. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73: 2680-2686.
29. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10: 1-10.
30. Mander AP, Thompson SG. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemp Clin Trials. 2010;31: 572-578.
31. Glynne-Jones R, Hughes R. Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99: 897-909.
32. Wynn GR, Bhasin N, Macklin CP, George ML. Complete clinical response to neoadjuvant chemoradiotherapy in patients with rectal cancer: opinions of British and Irish specialists. Colorectal Dis. 2010;12: 327-333.
33. Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194: 131-135.
34. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? Dis Colon Rectum. 2008;51: 10-19.
35. Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis. 2006;8(suppl 3): 21-24.
36. Maretto I, Pomerri F, Pucciarelli S, et al. The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2007;14: 455-461.
37. Perez RO, Habr-Gama A, Pereira GV, et al. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? Colorectal Dis. 2012;14: 714-720.
38. Lambregts DM, Maas M, Bakers FC, et al. Long-term followup features on rectal MRI during a wait-and-see approach after a clinical complete response in patients with rectal cancer treated with chemoradiotherapy. Dis Colon Rectum. 2011;54: 1521-1528.
39. Perez RO, Habr-Gama A, Gama-Rodrigues J, et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). Cancer. 2012;118: 3501-3511.
40. van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol. 2011;98: 126-133.
41. Perez RO, Habr-Gama A, São Julião GP, Proscurshim I, Scanavini Neto A, Gama-Rodrigues J. Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates. Dis Colon Rectum. 2011;54: 545-551.